Replying to Mauro Rebelo

PHARMA has a +defined/validated/fair #businessmodel. Sub-licensing assesses opportunity by peak sales of the drug and anticipates revenue + royalties for #bioprospecting. Future contracts finance development. The risk of each stages is mapped. It can be improved, but it's good.4⃣
f5
Mauro Rebelo 2y ago

#COSMETICS does not have a defined #businessmodel for #DISCOVERY. It uses small quantities in many products. Evaluates based on the volume supplied and not sold. It invests little and less in #bioprospecting which is not systematic. But… 5⃣

Reply to this note

Please Login to reply.

Discussion

f5
Mauro Rebelo 2y ago

The GREAT opportunity in the #longevity market is in #RegenerativeCosmetics because the pharma regulations are not ready for drugs to PREVENT diseases. When the sector realizes this, INVESTMENT will be ACCELERATED because the INCENTIVES are enormous. 6⃣